2018 News Releases

2018 | 2017 | 2016
DateTitle 
06/13/18Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
AUSTIN, Texas, June 13, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced the company recently began clinical studies for the Gastrointestinal (GI) Assay on the VERIGENE® II System, its new sample to answer benchtop molecular diagnostic system in development. The VERIGENE System enables clinicians to rapidly identify the pathogens responsible for some of the most complex, costly, and deadly human infectious diseases. The system offers automated, cost-effective multiplex ... 
Printer Friendly Version
05/18/18Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
AUSTIN, Texas, May 18, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer of Luminex will participate in an analyst-led fireside chat at the UBS Global Healthcare Conference to be held May 21, 2018 and will present at the Jefferies 2018 Global Healthcare conference to be held June 5, 2018.  Both presentations will take place in New York, NY. The UBS Global Healthcare Conference fireside chat will begin at 8:00 a.m. E... 
Printer Friendly Version
05/18/18Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 18, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2018 of $0.06 per share of common stock payable on July 13, 2018 to stockholders of record as of the close of business June 22, 2018. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide ran... 
Printer Friendly Version
05/07/18Luminex Corporation Reports First Quarter 2018 Financial Results
AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) today announced financial results for the first quarter of 2018.  Financial and operating highlights for the quarter include: First quarter 2018 consolidated revenue was $82.7 million, an increase of 6% compared to the first quarter 2017. First quarter 2018 GAAP net income was $13.4 million, or $0.30 per diluted share, growth of 45% and 43% respectively, over the prior year quarter. Assay revenue was... 
Printer Friendly Version
04/16/18Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018
AUSTIN, Texas, April 16, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2018 on Monday, May 7, 2018. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2018 on May 7, 2018, at 4:30 p.m. Eastern time. The co... 
Printer Friendly Version
03/08/18Luminex Corporation to Present at the Barclays Global Healthcare Conference
AUSTIN, Texas, March 8, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 13-15, 2018, in Miami. The investor presentation will begin at 4:50 p.m. Eastern time on Wednesday, March 14, 2018. The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section... 
Printer Friendly Version
02/12/18Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
AUSTIN, Texas, Feb. 12, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2017.  Financial and operating highlights for the quarter and full-year include: Fourth quarter and full-year 2017 consolidated revenue was $78.2 million and $306.6 million, an increase of 8% and 13%, respectively, compared to the fourth quarter and full-year 2016. Assay revenue was $41.8 million and $154.9 million for the quarter and ... 
Printer Friendly Version
02/06/18Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference
AUSTIN, Texas, Feb. 6, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7th Annual Global Healthcare Conference to be held February 14-15, 2018, in New York, NY. The investor presentation will begin at 10:30 a.m. Eastern time on Thursday, February 15, 2018.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address ... 
Printer Friendly Version
01/24/18Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas, Jan. 24, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of 2018 of $0.06 per share of common stock payable on April 13, 2018 to stockholders of record as of the close of business on March 23, 2018. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.  We offer a wide ... 
Printer Friendly Version
01/07/18Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 7, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2017 to be approximately $78 million and to exceed $306 million for the full- year ended 2017. These expected results reflect increases of 8% and 13% compared to the respective periods in 2016. Select fourth quarter highlights include: Total MDx revenue of approximately $44 million, grew 12% over the fourth quarter of 2016 The MDx s... 
Printer Friendly Version